Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New combo therapy aims to shield kidneys in african american veterans

NCT ID NCT07155694

Disease control Sponsor: Washington D.C. Veterans Affairs Medical Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Aug 21, 2026 · Updated 2 times

Summary

This study tests two drugs, finerenone and empagliflozin, in 30 African American veterans with diabetic kidney disease. The goal is to see if these drugs reduce kidney cell damage by measuring specific proteins in urine. Participants will take one or both drugs for 4 months to check for protective effects.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Finerenone (Kerendia) and Empagliflozin (Jardiance)
What this could lead to
If successful, this could show that finerenone, alone or with empagliflozin, helps protect kidney health in African American veterans with diabetic kidney disease.
What could go wrong
This is a small early-phase trial with only 30 participants, so results may not apply to everyone. The study looks at markers in urine, not long-term outcomes like kidney failure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 30 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Oct 2026

An estimate. Start dates often move.

Expected to finish

Aug 2027

An estimate. End dates often move.

Lead sponsor

A government agency

The lead sponsor is a US federal agency other than the NIH.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

20 to 90 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Diagnosis of type 2 diabetes (HbA1C at or above 6.5%, or fasting blood glucose of more than 125 or random/ post prandial blood glucose of more than 199mg%) 2. African American veterans 3. Age 20-90 years 4. eGFR ≥25-89 mL/min/1.73 m2 by the CKD-EPI equation) 5. Albuminuria of 30 mg/g or higher 6. BMI=18-39.9 7. Blood pressure controlled to ≤140/90 8. Ability to provide informed consent before any trial related activities are conducted. Exclusion Criteria 1. If a patient is on statin, need to be on a stable dose for a month. 2. Biopsy proven diagnosis of glomerular disease/glomerulonephritis 3. Active smokers, 4. Active skin wounds undergoing treatment or recent surgery within 1 month (due to possible aberrations in glycemic control) 5. Women who are pregnant, planning to become pregnant, nursing mothers, women of childbearing potential not using birth control measure 6. Hypersensitivity to empagliflozin or finerenone 7. Patients on dialysis 8. eGFR less than 25 mL/min/1.73 m2 by the CKD-EPI equation 9. Planned surgery or planned hospital admission within 5 months of participation in the study 10. At the discretion of PI to ensure health, safety, and well-being of the veteran, participation in this study may be stopped (please see withdrawal criteria) 11. Patients with prior history of diagnosis of heart failure with documented EF of less than 50. 12. Proven diagnosis of Polycystic Kidney Disease.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Diabetic kidney disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic renal failure syndrome diabetes mellitus diabetic kidney disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Diabetic kidney disease

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Washington DC Veterans Affairs Medical Center (688)

    Washington D.C., District of Columbia, 20422, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.